Skunkworx

Skunkworx Bio was a biotechnology drug discovery subsidiary created by Heat Biologics, later part of NightHawk Biosciences, focused on building precision medicines from antibody and small protein libraries. The company described its core approach as "Pocket Biologics," combining biologic discovery with computational and bioinformatic analysis to identify targets and advance lead candidates toward preclinical development. Publicly available information indicates that Skunkworx Bio operated as an early-stage discovery platform company rather than a clinical-stage therapeutic developer. The business appeared to remain within the NightHawk/Scorpius ecosystem until the parent group’s financial distress and 2026 foreclosure process affecting subsidiaries and R&D assets. There is no clear public evidence of an independent marketed product or advanced clinical pipeline under the Skunkworx Bio name.